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Context: Metabolic inflexibility, ie, the impaired ability of the body to switch from fat to carbo-
hydrate oxidation under insulin-stimulated conditions, is associated with insulin resistance. This
alteration inmetabolic plasticity can lead toorgandysfunctionand is consideredakey issueamong
the abnormalities of themetabolic syndrome. It is still unknownwhether this phenomenon occurs
in women with polycystic ovary syndrome (PCOS).
Objective: Our objective was to examine whether metabolic inflexibility is a feature of PCOS
women and whether hyperandrogenism may contribute to this phenomenon.
Design and Patients: Eighty-nine Caucasian women with PCOS were submitted to hyperinsulinemic-
euglycemic clamp. Respiratory exchange ratios were evaluated at baseline and during hyperinsulin-
emia by indirect calorimetry to quantify substrate oxidativemetabolism. Total testosteronewasmea-
sured by liquid chromatography mass spectrometry and free testosterone by equilibrium dialysis.
Setting: Outpatients were seen in a tertiary care academic center.
Main Outcome Measure:Metabolic flexibility was assessed by the change in respiratory quotient
upon insulin stimulation.
Results: Sixty-five of the 89 PCOSwomen (73%)had increased serum free testosterone, 68 (76%)were
insulin resistant, and 62 (70%) had an impaired metabolic flexibility. Comparison of hyperandrogen-
emic and normoandrogenemicwomen showed that the 2 subgroupswere of similar age but differed
in terms of several anthropometric andmetabolic features. In particular, hyperandrogenemicwomen
had greater body mass index (32.9 1.0 vs 24.7 0.9 kg/m2, P .001) and lower glucose utilization
during the clamp (9.2 0.4 vs 10.9 0.7mg/kg fat-freemass · min, P .023) andmetabolic flexibility
(0.09 0.06 vs 0.12 0.01, P .014). In univariate analysis, metabolic flexibility was associated with
several anthropometric, endocrine, and metabolic features. In multivariate analysis, this feature was
directly associated with baseline respiratory quotient and insulin sensitivity and inversely with free
testosterone and free fatty acids concentrations under insulin suppression (R2 0.634, P .001).
Conclusions: Metabolic inflexibility is a feature of PCOS women. Both insulin resistance and an-
drogen excessmight contribute to this abnormality. (J Clin EndocrinolMetab 98: 2581–2588, 2013)
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Metabolic flexibility is the capacity for the body torapidly switch from predominant lipid oxidation
with high rates of fatty acid uptake in low insulin condi-
tions to predominant glucose oxidation and storage with
suppression of lipid oxidation in high insulin conditions
(1). This physiological adaptive metabolic change is re-
flected by an increase in the respiratory quotient (RQ), ie,
in the CO2 produced to O2 consumed ratio (1). The RQ is
0.7 when only fat is burned, whereas it rises to 1.0 when
energy balance relies entirely on glucose oxidation (2).
Intermediate values indicate that both sources are used.
Previous research showed that obese and/or diabetic
individuals, as compared with healthy lean individuals,
have an impaired metabolic flexibility (3). Interestingly, a
similar finding was reported for insulin-resistant nondia-
betic individuals with a family history of type 2 diabetes
(4), suggesting this phenomenonmaybe directly related to
the impaired insulin action.
Insulin resistance and the associated metabolic abnor-
malities are frequent findings in women with polycystic
ovary syndrome (PCOS) (5).However, until now,no stud-
ies have assessed whether these women have an altered
metabolic flexibility. Moreover, it is unknown whether
androgen excess, which is associated with insulin resis-
tance andmay affect adipose tissuemetabolism, may con-
tribute to this alteration.
The aims of this study were to assess 1) whether met-
abolic flexibility is impaired in PCOSwomen, and 2) if so,
whether hyperandrogenism may contribute to this
phenomenon.
To answer these questions, respiratory exchange ratios
were assessed by indirect calorimetry at baseline and dur-
ing a hyperinsulinemic-euglycemic clamp in 89Caucasian
PCOSwomen. Serumtestosteronewasmeasuredby liquid
chromatographymass spectrometry, and free testosterone
fraction was estimated by equilibrium dialysis, the gold
standard for this assay.
Subjects and Methods
Subjects
Eighty-nine nondiabetic, Caucasian womenwith PCOSwere
examined.Mean age was 23.6 0.6 years and body mass index
(BMI) was 30.7  0.9 kg/m2. They were among the patients
recruited in the Verona PCOS Pathophysiology and Phenotype
(Verona 3P) Study, an ongoing project aimed at building a com-
prehensive database for exploring the relationships between the
different features of these women. All these subjects were re-
ferred to the outpatient clinic of the Division of Endocrinology,
Diabetes, and Metabolism of Verona Hospital, Italy, for hirsut-
ism and/or menstrual alterations, and PCOS diagnosis was es-
tablished according to the Rotterdam criteria (6). In particular,
66 of these 89 women had the classic PCOS phenotype (ie, they
showed both clinical and/or biochemical hyperandrogenism and
chronic oligo-anovulation), whereas 23 had either the ovulatory
or the normoandrogenic phenotypes. Further details on this co-
hort have been reported elsewhere (7). Inclusion criteria were a
confirmed PCOS diagnosis and age 18 to 40 years. Exclusion
criteria were diabetes mellitus or other diseases or medications
potentially interfering with the evaluations carried out in the
study. For PCOS diagnosis, hyperandrogenism was defined by
the presence of hirsutism and/or increased serum free testoster-
one. In accordance with the Androgen Excess and PCOS Society
guidelines for diagnosis of PCOS, other clinical features, such as
acne or alopecia, and serum androgens other than free testos-
terone were not used, because they are less specific and add a
limited incremental amount to PCOS diagnosis (8). Consistent
with this statement, in our sample, only a single (nonhirsute)
PCOS patient among those with normal serum free testosterone
showed a mild increase in serum androstenedione. Chronic oli-
goanovulation was diagnosed by the presence of either oli-
goamenorrhea (fewer than 9 cycles per year) or luteal-phase se-
rumprogesterone below12nmol/L. Specific endocrine disorders
were excluded by assessment of serum17-hydroxyprogesterone,
TSH, and prolactin, whereas other investigations were carried
out when indicated on clinical grounds.
Data previously obtained in a historical sample of 24 healthy
volunteers, with regular menses, normal ovarian morphology
and no clinical evidence of hyperandrogenism, served to define
the reference intervals for insulin sensitivity and metabolic flex-
ibility. Fifty-one women with the same characteristics served to
define the reference interval for serum free testosterone. The two
groups of healthy women were similar in terms of both age
(26.6 3.6 vs 28.3 6.0 years) and BMI (21.9 2.0 vs 21.1
2.0 kg/m2).
All subjects gave their informed written consent before the
study, which was conducted in accordance with the Declaration
of Helsinki and approved by the institutional ethics committee.
Protocol
All subjects underwent a complete physical examination, in-
cluding assessment of height, body weight, waist circumference,
and blood pressure (BP). Body fat and fat-free mass (FFM) were
measured by bioelectrical impedance (BIA103;Akern, Florence,
Italy) (9).
After an overnight fast, blood samples for serum testosterone
and metabolic parameters were collected. The metabolic assess-
ment included an oral glucose tolerance test (OGTT) with mea-
surement of plasma glucose and insulin at baseline and every 30
minutes for 2 hours.
On a separate day, a hyperinsulinemic-euglycemic clampwas
carried out to assess whole-body insulin-stimulated glucose uti-
lization (10). In the basal, non–insulin-stimulated period and
under steady-state hyperinsulinemic clamp conditions, indirect
calorimetrywas performed tomeasure theRQandquantify sub-
strate oxidation (2).
Hyperinsulinemic-euglycemic clamp and indirect
calorimetry
After overnight fasting, iv catheters were inserted in an an-
tecubital vein of an arm for infusions and in a dorsal hand vein
of the contralateral arm for arterialized blood sampling. After
baseline sampling, a primed-continuous insulin infusion (Hu-
mulin R; Eli Lilly & Co, Indianapolis, Indiana) was started and
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maintained for 2 to 3 hours at a constant rate of 80 mU/m2/min.
Euglycemia (serum glucose concentrations at approximately 90
mg/dL) was concurrently maintained throughout the clamp by a
variable infusion of 20% dextrose, adjusted by monitoring
plasma glucose levels in arterialized venous blood, approxi-
mately every 5 to 10 minutes. Sampling for assessing serum in-
sulin and other parameters (free fatty acids [FFAs]) was made at
baseline and in the last 30 minutes of the clamp at 10-minute
intervals. We previously found that in nondiabetic hyperandro-
genic subjects and control women, endogenous glucose produc-
tion was negligible at this insulin infusion rate (11). Therefore,
the amount of glucose infused can be considered equivalent to
whole-body insulin-stimulated glucose utilization. Becausemus-
cle is responsible formost insulin-stimulated glucosemetabolism
(12), the mean glucose infusion rate during the steady-state pe-
riod (last 30 minutes) of the clamp was normalized for FFM.
Resting RQ and glucose and lipid oxidation rates were mea-
sured over 30 minutes at baseline and at steady state during the
clamp by indirect calorimetry using a Quark RMR instrument
(Cosmed, Cernusco sul Naviglio, Italy) equipped with a venti-
lated hood.
Assays
Plasma glucose was assayed by a glucose analyzer (YSI 2300
STAT PLUS, Yellow Springs, Ohio). Serum total testosterone
wasmeasured by liquid chromatographymass spectrometry, us-
ing a Micromass Quattro Premier XE mass spectrometer from
Waters Corporation (Milford, Massachusetts). The limit of
quantification was 2.5 ng/dL, and the intra-assay coefficient of
variation was 9.1% at a concentration of 14 ng/dL and the in-
terassay coefficient of variation was 9.3% at a concentration of
26 ng/dL. Free testosterone fraction was estimated by equilib-
rium dialysis (13, 14) with an interassay coefficient of variation
8%.
SHBG and insulin were assayed by immunoradiometric
methods (Orion Diagnostica, Espoo, Finland; and Biosource,
Fleurus, Belgium, respectively). Serum FFAs were measured in a
sample of 54 women by an enzymatic colorimetric assay (Wako
Chemicals GmbH, Neuss, Germany).
Calculations
Glucose and lipid oxidation rates were calculated using stan-
dard formulas (2). In this analysis, the protein oxidation ratewas
assumed to be equal to 31.2 mg/min, the mean value previously
obtained in our lab bymeasuring nitrogen urinary excretion rate
in a sample of PCOS subjects submitted to the same protocol. By
including this figure, it is possible to calculate the nonproteinRQ
(npRQ),which reflects glucose and lipidoxidationonly (2).Met-
abolic flexibility was calculated as the difference between the
npRQvalue obtained in the steady-state period of the clamp and
the fasting npRQ. Nonoxidative glucose metabolism was calcu-
lated as the difference between total glucose utilization and glu-
cose oxidation rate. Low-density lipoprotein (LDL)-cholesterol
was estimated by the Friedewald formula (15).
Statistical analysis
Data were summarized by means and SEs. Normality of the
distribution of the variables was assessed by the Shapiro-Wilk
test. Skewed variables were log or square root transformed be-
fore analysis.
The Student’s t test for unpaired data was used to compare
groups of hyperandrogenemic and normoandrogenemic PCOS
women, and 1-way ANOVAwas used to compare subgroups of
these women divided into tertiles of metabolic flexibility. Asso-
ciations between metabolic flexibility and each variable of in-
terest were assessed by Pearson correlation coefficients (r). The
Mann-WhitneyU test andSpearmanrankcorrelationswereused
when variables could not be normalized.
To assess predictors of metabolic flexibility, multiple regres-
sion analysis was performed, using metabolic flexibility as the
dependent variable and baseline npRQ, age, total fatmass, waist
circumference, glucose tolerance (2-hour OGTT glucose), insu-
lin sensitivity (glucose disposal rate during clamp), serum FFAs
under hyperinsulinemia, and free testosterone as independent
variables. In these analyses, independent variables were chosen
on the basis of associations in univariate analyses with the de-
pendent variable and/or of biological plausibility.
P values .05 were considered statistically significant. Anal-
yses were carried out using STATA version 12.1 (StataCorp,
College Station, Texas).
Results
Table 1 shows themain characteristics of the entire sample
of PCOS women included in the study, either as a whole
or stratified into hyperandrogenemic and normoandro-
genemic subgroups. In the whole sample, mean BMI was
30.7 kg/m2. Among the metabolic features, mean glucose
levels at fasting and afterOGTTwerewithin the reference
intervals, whereas plasma insulin concentrations were in-
creased. A reduction in serum high-density lipoprotein
(HDL)-cholesterol was the only abnormality in the lipid
profile.
Sixty-five of the 89 PCOSwomen (73%) had increased
serum free testosterone levels. Comparison of hyperan-
drogenemic and normoandrogenemic women showed
that the 2 subgroups differed in terms of a number of
anthropometric and metabolic features (Table 1). In par-
ticular, total body fat, waist circumference, and fasting
glucose and insulin levels were significantly higher in hy-
perandrogenemic subjects.
Table 2 shows the measures of insulin action and sub-
strate utilization obtained by the glucose clamp procedure
combined with indirect calorimetry. In the whole sample,
the mean glucose disposal rate during clamp (M-clamp
value) was below the lower limit of the reference interval
for our lab (11.75 mg/kg FFM · min), and most subjects
(n 68, 76%) were insulin-resistant. The metabolic flex-
ibility, measured by the increase in npRQ frombaseline to
insulin-stimulated conditions, was also reduced in PCOS
women (reference value in our healthy women0.12). In
particular, 62 (70%) of these patients showed impaired
metabolic flexibility.
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Comparison of hyperandrogenemic and normoandro-
genemic PCOS subjects showed that the impairment in
insulin action was more severe in the former (Table 2).
Differences between these subgroups in nonoxidative glu-
cose metabolism accounted for most of the reduction in
insulin-stimulated glucose utilization found in hyperan-
drogenemicwomen.Metabolic flexibilitywas impaired to
a greater extent in hyperandrogenemic than in normoan-
drogenemic PCOS subjects (Table 2 and Figure 1). This
difference was confirmed also after adjusting for glucose
disposal rate and fat mass.
Conversely, serum free testosterone levels significantly
differed between subgroups of PCOSwomen divided into
tertiles ofmetabolic flexibility (P .005). Interestingly, in
post hoc analysis, serum free testosterone levels of subjects
in the lower tertile of metabolic flexibility differed from
those of subjects in both the upper (P  .006) and the
intermediate (P  .038) tertiles, whereas the latter had
similar free testosterone concentrations (P .520). These
results were maintained after controlling for glucose dis-
posal rate and fat mass. Three normoandrogenemic vs 27
hyperandrogenemic subjects (12% vs 42% of the respec-
Table 2. Substrate Metabolism at Baseline and During the Clamp in the Whole Cohort of PCOS Women Included
in the Study and in the Subgroups of Hyperandrogenemic and Normoandrogenemic Patientsa
Features All Hyperandrogenemic Normoandrogenemic
Baseline npRQ 0.726  0.006 0.732  0.007 0.709  0.010
Metabolic flexibility (npRQ) 0.098  0.005 0.091  0.060 0.120  0.010b
Glucosal disposal rate, mg/kg FFM/min 9.63  0.34 9.16  0.39 10.91  0.68b
Glucose oxidation (baseline), mg/kg FFM/min 0.53  0.08 0.60  0.10 0.31  0.10
Glucose oxidation (clamp), mg/kg FFM/min 2.20  0.11 2.19  0.14 2.30  0.18
Nonoxidative glucose metabolism (clamp), mg/kg FFM/min 7.41  0.31 7.0  0.35 8.61  0.63b
Lipid oxidation (baseline), mg/kg FFM/min 1.83  0.05 1.78  0.06 1.96  0.10
Lipid oxidation (clamp), mg/kg FFM/min 1.24  0.05 1.25  0.06 1.21  0.08
a Data are shown as mean  SE.
b P  .05–.01 vs hyperandrogenemic patients.
Table 1. Main Characteristics of the Whole Cohort of PCOS Women Included in the Study and of Subgroups of
Hyperandrogenemic and Normoandrogenemic Subjects, With the Corresponding Reference Intervalsa
Features
All
n  89
Hyperandrogenemic
n  65
Normoandrogenemic
n  24
Reference
Interval
Age, y 23.6  0.6 23.4  0.7 24.3  1.1 NA
BMI, kg/m2 30.7  0.9 32.9  1.0 24.7  0.9e 18–25
Waist circumference, cm 95.9  2.0 100.9  2.4 82.2  2.4e 80
Fat mass, kg 30.9  1.5 34.3  1.9 21.8  1.6e
FFM, kg 50.9  1.1 53.1  1.3 44.9  1.1e
Ferriman-Gallwey score 10.6  0.8 11.0  0.9 9.3  1.6 8
Systolic BP, mm Hg 121  2 122  2 118  3 130
Diastolic BP, mm Hg 79  1 79  1 78  2 85
Fasting glucose, mg/dL 87  1 89  1 82  1d 70–99
Fasting insulin, mU/L 18  1.4 20.5  1.7 11.0  1.4e 9.0
2-h glucose OGTT, mg/dL 103  4 106  4 93  6 140
Total cholesterol, mg/dL 165  3 167  4 159  6 200
HDL-cholesterol, mg/dLb 48.4  1.3 46.3  1.5 54.0  2.1e 50
LDL-cholesterol, mg/dLb 100  2.7 103  3.1 91  5.0d 130
Triglycerides, mg/dLc 85.1  6.4 91.4  8.2 68.2  7.5 150
SHBG, nmol/L 32.5  1.9 29.2  2.0 41.4  3.9e 39–121
Total testosterone, ng/dL 37.6  1.6 42.1  2.2 25.4  2.2e 41
Free testosterone, ng/dL 0.76  0.04 0.90  0.04 0.39  0.02e 0.50
Ovarian follicles, n 13  1 13  1 13  1 12
Ovarian volume, mL 11.4  0.5 11.5  0.5 11.2  1.1 10
Abbreviation: NA, not applicable.
a Data are shown as mean  SE.
b Not available in 2 subjects.
c Not available in 1 subject.
d P  .05–.01 vs hyperandrogenemic patients.
e P  .01–.001 vs hyperandrogenemic patients.
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tive subgroups, P .011) were in the lower tertile of met-
abolic flexibility.
SerumFFA levels at baseline and during the clampwere
similar in both hyperandrogenemic and normoandrogen-
emic PCOS women (607  25 vs 566  39 Eq/L, P 
.381; and 74.5  4.2 vs 65.6  7.2 Eq/L, P  .189,
respectively).
As shown inTable 3,metabolic flexibilitywas inversely
associated with the basal npRQ value and with a number
of anthropometric, endocrine, and metabolic features
(BMI,waist circumference, total-body fatmass, BP, serum
free testosterone, insulin, triglycerides, 2-hour OGTT
plasma glucose, and FFA levels during the clamp). Con-
versely, it was directly associated with glucose disposal
rate and serum HDL-cholesterol.
In multiple regression analysis, metabolic flexibility
was independently associated with baseline npRQ value,
glucose disposal rate, free testosterone levels, and FFA
concentrations under insulin suppression (Table 4; overall
R2  0.634, P  .001). When free testosterone was re-
placed by total testosterone and SHBG in the multiple
regression analysis, total testosterone (P  .031) but not
SHBG (P  .127) was associated with metabolic
flexibility.
Discussion
This is the first study to investigate metabolic flexibility of
PCOS women and to explore which features are associ-
ated with this phenomenon. Our data showed that PCOS
women have an impaired ability to shift their substrate
metabolism from a condition of predominant lipid oxi-
dation at low (fasting) insulin levels toward a condition of
predominant glucose oxidation at high (clamp) insulin
levels. Metabolic plasticity is fundamental in adaptation
and the inability to adjust to variations in energy demand
and substrate fluxes can lead to organ dysfunction and,
eventually, disease. In this regard, it is noteworthy that a
number of data point to metabolic inflexibility as a key
dysfunction among the abnormalities featuring the met-
abolic syndrome (16).Moreover, it was hypothesized that
metabolic inflexibility may lead to ectopic fat accumula-
tion in insulin-sensitive tissues, such as liver and skeletal
muscle (17). In turn, this phenomenonmay cause hepatic/
systemic insulin resistance and atherogenic dyslipidemia
aswell as inflammation and fibrosis in the liver, being also
linked to an increased risk of cardiovascular events (18).
Interestingly, in our study, metabolic flexibility was in-
dependently associated with baseline npRQ values and
metabolic and endocrine parameters such as whole-body
insulin-stimulated glucose metabolism, FFA concentra-
tions under insulin suppression, and androgen levels.
The association betweenmetabolic inflexibility and in-
sulin resistance was previously reported in other condi-
tions characterized by an impaired insulin action, such as
obesity and type 2 diabetes (19, 20). Galgani et al (20)
suggested that the altered sensitivity of tissues to insulin
action on glucose metabolism may explain most if not all
of this phenomenon. However, the same group subse-
quently reported that metabolic flexibility was higher in
African-Americans than in Caucasians as well as in non-
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Figure 1. Box plots of metabolic flexibility in hyperandrogenemic and
normoandrogenemic PCOS women. Data are compared with reference
values of healthy controls. P  .014 between subgroups of PCOS
women; P  .001 between healthy women and both PCOS subgroups.
Table 3. Associations (Pearson’s r) Between Metabolic
Flexibility (npRQ) and Anthropometric, Metabolic, and
Hormonal Parameters in the Whole Population of PCOS
Women
r Pa
Baseline npRQ 0.464 <.001
Age 0.164 .124
BMI 0.406 <.001
Waist circumference 0.356 <.001
Fat mass 0.406 <.001
FFMb 0.355 <.001
Systolic BP 0.313 .003
Diastolic BP 0.272 .010
Free testosterone 0.341 .001
Fasting insulin 0.464 <.001
Fasting glucose 0,173 .104
2-h glucose OGTT 0.234 .030
Glucose disposal rate 0.453 <.001
Total cholesterol 0.200 .062
HDL-cholesterol 0.331 .002
Triglycerides 0.248 .020
LDL-cholesterol 0.267 .012
FFA, baseline 0.033 .784
FFA, clamp 0.432 .001
a Statistically significant P values are in bold.
b -Value, by nonparametric Spearman correlation.
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diabetic than in diabetic subjects even after adjusting for
glucose disposal rate, suggesting that factors different
from insulin resistance may independently contribute to
this metabolic abnormality (21). Yet it was reported that
metabolic inflexibility may precede insulin resistance of
glucose metabolism in prediabetic subjects (22), consis-
tent with the conclusion that this phenomenon is not sim-
ply a manifestation of insulin resistance. Although the
mechanisms underlying the association between insulin
resistance and metabolic inflexibility are not fully under-
stood, a body of literature indicates that insulin-resistant
subjects have a mitochondrial dysfunction caused by a
reduction in the number of mitochondria in skeletal mus-
cle and/or an intrinsic functional defect of them (23, 24).
It was hypothesized that the mitochondrial defect may
primarily induce impaired fat oxidation and increased fat
accumulation in themuscle (25). In turn, this phenomenon
may impair insulin signaling, thus inducing a defect in
both oxidative and nonoxidative glucosemetabolism (24,
26, 27). Interestingly, when this alteration occurs, mito-
chondria oxidative pathways seem to prefer FFAs to glu-
cose (25), thus explaining the finding of an altered meta-
bolic flexibility.
Another alteration previously linked to metabolic in-
flexibility is the impaired suppression by insulin of FFA
release (ie, lipolysis) (16, 20). It is noteworthy that im-
paired serum fatty acid reduction during insulin infusion
is another manifestation of abnormal insulin action, oc-
curring at the adipose tissue level. However, the indepen-
dent association between metabolic inflexibility and this
phenomenon, in a model also including a measure of in-
sulin action on glucose metabolism, indicates that serum
FFA concentrations during hyperinsulinemia carry sup-
plemental information. It is noteworthy that similar find-
ings were previously reported in obese diabetic and non-
diabetic subjects (20). This is consistent with a tissue-
specific sensitivity (or resistance) to insulin, which
accounts for thepoor correlationbetween the effects of the
hormone onmuscle and adipose tissue (28). In pathophys-
iological terms, increased serum FFA levels may contrib-
ute to impaired glucose oxidation (25). This phenomenon
may explain the observation of Randle et al (29) who
proposed a glucose-fatty acid cycle to describe the dy-
namic interactions between these substrates. In addition,
the increased exposure of tissues to FFAs can induce in-
hibition of insulin signal, thus contributing to the further
worsening of insulin resistance (22, 30, 31).
Interestingly, a novel and intriguing finding of this
study is that serum free testosterone levels were an addi-
tional predictor of metabolic inflexibility in these women,
independent of muscle and adipose tissue insulin resis-
tance and body fat. These data give further support to the
hypothesis that androgens may play a direct role in the
regulation of metabolic processes. Interestingly, a change
in capillary density and fiber composition, with reduction
in type 1 oxidative and increase in type 2 glycolytic fibers,
was previously reported in ovariectomized rats exposed to
a moderate androgen excess (32). Moreover, testosterone
administration may increase FFA oxidation and decrease
glucose oxidation, independently of changes in whole-
body insulin-stimulated glucose metabolism (33). Consis-
tently, testosterone increased palmitate oxidation while
increasing nonoxidative but not oxidative metabolism of
glucose in isolated myotubes from postmenopausal
women (34).
The main strengths of this study are the relatively large
sample size, the comprehensive assessment of subjects,
and the measurement of several parameters (e.g., insulin
sensitivity, free testosterone, etc.,) by state-of-the-art
techniques.
We also acknowledge some limitations in the study.
The first limitation is intrinsic to the different character-
istics of normoandrogenic and hyperandrogenic PCOS
women. It is well known that these subgroups of PCOS
Table 4. Predictors of Metabolic Flexibility ( npRQ) by Multiple Regression Analysis in the Whole Group of PCOS
Subjects (R2  0.634, P  0.001).
Features -Coefficient SE Pa
Baseline npRQ 0.586 0.110 <.001
Glucose disposal rate, mg/kg FFM/min 0.007 0.002 .002
FFA (clamp),b Eq/L 0.574 0.218 .012
Free testosterone, ng/dL 0.047 0.019 .017
Waist circumference,c cm 0.006 0.003 .090
2-h glucose OGTT,d mg/dL 0.001 0.002 .689
Fat mass, kg 0.001 0.001 .911
Age, y 0.001 0.001 .986
a Statistically significant P values are in bold.
b Available in 54 subjects.
c -Coefficient was calculated on the basis of an increase of 5 cm.
d -Coefficient was calculated on the basis of an increase of 10 mg/dL.
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women differ in terms of body fat mass, fat distribution,
and metabolic features (7, 35). Therefore, heterogeneity
between groups is unavoidable when samples of unse-
lected consecutive PCOS women are recruited, as was the
case in our study. The mechanisms underlying the asso-
ciation between obesity and hyperandrogenism remain
largely unknown, and it was hypothesized that this rela-
tionship could be bidirectional. To overcome this prob-
lem,we performedmultivariable analysis inwhich several
features that differed between groups were included as
independent variables to assess the specific role of andro-
gen excess in the impaired metabolic flexibility. An alter-
native approach couldbe the comparisonofBMI-matched
women. However, obesity is uncommon in our normoan-
drogenic PCOS subjects. Moreover, recruitment of hy-
perandrogenic and normoandrogenic PCOS women with
a similar BMI would necessarily result in samples that are
not fully representative of their respective populations. In
addition, it is likely that fatmass excess in obese normoan-
drogenic andhyperandrogenicPCOSwomenmaydiffer in
terms of origin, distribution, and pathophysiology.
Second, our sample was constituted entirely of Cauca-
sian women. Therefore extrapolation of these results to
other ethnic groups should be undertaken with caution.
Finally, in our sample of historical healthy controls used to
define the reference interval formetabolic flexibility,mea-
surement of serum testosterone bymass spectrometry and
equilibrium dialysis was not available, precluding assess-
ment of any role of androgens in metabolic flexibility of
healthywomen. This would be an interesting point. How-
ever, it is likely that the sample size required to address this
issue would need to be very large.
Overall, our findings demonstrate for the first time that
metabolic inflexibility is a feature of PCOS women and
that both insulin resistance and hyperandrogenism may
contribute to impaired insulin-stimulated glucose oxida-
tion in these subjects. Future prospective studies are
needed to assess towhat extent these findingsmayaccount
for the striking metabolic differences between hyperan-
drogenic and normoandrogenic PCOSwomen and for the
increased visceral and ectopic fat accumulation in these
subjects.
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